JY
AMLX icon

Jeff Yass’s Amylyx Pharmaceuticals AMLX Stock Holding History

Jeff Yass’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.28M Buy
405,300
+151,400
+60% +$2.34M ﹤0.01% 3919
2026
Q1 		$3.53M Buy
253,900
+145,600
+134% +$2.05M ﹤0.01% 4926
2025
Q4 		$1.31M Sell
108,300
-88,100
-45% -$1.2M ﹤0.01% 6572
2025
Q3 		$2.67M Buy
196,400
+54,000
+38% +$508K ﹤0.01% 5202
2025
Q2 		$913K Buy
142,400
+47,000
+49% +$229K ﹤0.01% 7672
2025
Q1 		$338K Buy
95,400
+38,400
+67% +$137K ﹤0.01% 9799
2024
Q4 		$215K Sell
57,000
-37,400
-40% -$176K ﹤0.01% 10566
2024
Q3 		$306K Sell
94,400
-7,200
-7% -$16.2K ﹤0.01% 9560
2024
Q2 		$193K Sell
101,600
-648,000
-86% -$1.26M ﹤0.01% 10411
2024
Q1 		$2.13M Buy
749,600
+593,900
+381% +$7.77M ﹤0.01% 5194
2023
Q4 		$2.29M Sell
155,700
-81,400
-34% -$1.25M ﹤0.01% 5084
2023
Q3 		$4.34M Sell
237,100
-202,400
-46% -$4.28M ﹤0.01% 3782
2023
Q2 		$9.48M Sell
439,500
-55,500
-11% -$1.5M ﹤0.01% 2565
2023
Q1 		$14.5M Buy
495,000
+245,800
+99% +$8.54M ﹤0.01% 2019
2022
Q4 		$9.21M Sell
249,200
-689,300
-73% -$24.5M ﹤0.01% 2377
2022
Q3 		$26.4M Buy
938,500
+830,800
+771% +$20.7M 0.01% 1191
2022
Q2 		$2.07M Buy
107,700
+85,500
+385% +$1.02M ﹤0.01% 4847
2022
Q1 		$285K Buy
+22,200
New +$501K ﹤0.01% 10393

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jeff Yass's AMLX Position: Q2 2026 in Review

Jeff Yass reduced its Amylyx Pharmaceuticals (AMLX) stake by 74% in Q2 2026, selling an estimated $456K and leaving 10,339 shares worth $186K. The position accounts for ﹤0.01% of the portfolio, ranked #12032.

Jeff Yass first reported a position in AMLX in Q1 2022 and has held it in 16 quarters since. The position peaked at $8.29M in Q4 2023. 205 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Jeff Yass held 10,339 shares of Amylyx Pharmaceuticals worth $186K as of Q2 2026.
  • Jeff Yass sold 29,463 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $456K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12032 holding.
  • Jeff Yass first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 16 quarters since.
  • Jeff Yass's Amylyx Pharmaceuticals position peaked at $8.29M in Q4 2023.
  • 205 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.